2 results for "revolution-medicines"
One patient with advanced pancreatic cancer saw no progression for 18 months on daraxonrasib. Here's what this means for future treatments and the broader lands
Daraxonrasib nearly doubled overall survival in pancreatic cancer patients, yet limited supply leaves patients like Amy Johnston grasping for access.
